Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study
Introduction
Lung cancer is the leading cause of cancer-related death for both men and women worldwide. Among the various treatment methods in use, thoracic radiation therapy (RT) remains arguably the most effective and most widely used treatment for locally advanced or medically inoperable non-small cell lung cancer (NSCLC), and limited disease small cell lung cancer (SCLC). A number of randomised studies and large meta-analyses have also demonstrated a survival advantage for patients (PTs) treated with combined chemoradiation [1]. Moreover, post-operative RT is still widely used even though it has been criticised by recent studies suggesting more strict patient selection criteria [2].
Radiation pneumonitis (RP), which manifests within a period of 1–8 months after radiotherapy (RT), is one of the most significant complications. RT-induced pulmonary symptoms occur in about 20% of all PTs irradiated for lung cancer or other thoracic neoplasms, while subclinical functional and radiological changes are seen in an even larger fraction of PTs [3], [5], [26].
Several studies have investigated the relationship between a number of clinical factors including age, gender, performance status, pulmonary comorbidity, tumour site, changes in plasma, cytokine transforming growth factor-β levels, histology and the development of severe RP [27], [29], [33], [37], [38]. Some authors have focused their analyses on PTs treated with combined modality treatment (chemoradiotherapy), for which an increased risk of RP has been postulated [8], [17], [18], [19], [31], [34], [36], [38]. However, most of these studies did not take into account 3D dosimetry data.
Previous reports have identified ‘simple’ dosimetric risk factors for RP [31]. More recently, however, based on the detailed dosimetric information provided by three-dimensional (3D) treatment planning tools, other researchers have related the risk and severity of RP to specific DVH parameters [4], [14], [15], [24], [28], and a few studies have characterised the dose–response curve for RP following RT by means of biological models [7], [12], [21].
While there are a number of differences in the published reports, there is some consensus about the association between a few of the dosimetric factors (mainly the mean lung dose Dmean) and the incidence of RP [15]. Most lung cancer PTs showed poor pre-treatment pulmonary function and among those patients, chronic obstructive pulmonary disease (COPD) was not an uncommon clinical finding. However, the role of pre-treatment lung function and the influence of covariates such as chemotherapy agents are still under debate [13], [35].
We herein report our experience of radiation induced pulmonary toxicity in a group of 84 patients with lung cancer, all with lung dose–volume histogram (DVHs) data, prescribed dose >40 Gy and >6 months of follow-up from the start of RT. As this is a retrospective study, no quantitative pulmonary function tests were available in all PTs; however, each patient was classified as having or not having pre-treatment COPD. We attempted to retrospectively identify clinical and dosimetric factors that could aid in the prediction of RP.
Section snippets
Patient eligibility
The records of all PTs with localised lung cancer and treated with radiotherapy (RT) in the Radiotherapy Department of Istituto Scientifico San Raffaele between November 1994 and August 2000, were reviewed with the intent of studying the lung response to radiation. A total of 84 PTs were identified who met the following inclusion criteria: limited disease SCLC (12 PTs) or NSCLC (72 PTs) treated with RT dose greater than 40 Gy, no pneumonectomy before or after RT, availability of CT-based 3D
Results
Fourteen PTs (16.7%) developed radiation pneumonitis: 12 grade II, one grade III and one grade V. The actuarial incidence at 6 and 12 months was 15.7±4.2% and 17.2±4.4%, respectively. The median time to development of RP was 4.5 months (range: 1–10 months). Radiographic films proved that all RPs were localised in the ipsilateral lung.
Univariate analysis was performed for several clinical and dosimetric factors to analyse their impact on the development of RP and the results are summarised in
Discussion
Recently Seppenwoolde and Lebesque [35] have reviewed the role of patient specific aspects, dosimetric factors and model calculations in quantifying the effects of partial lung irradiation. Both simple dosimetric parameters (such as Dmean or V20) and NTCP models are associated with the incidence of RP, but accurate predictability should include pre-existent pulmonary function and other potential covariates, such as anticancer drugs. This paper reports the results of a retrospective single
Conclusions
In summary, the results of this retrospective study showed a significant correlation between pre-treatment COPD and the risk of RP. There was a higher risk of RP in patients treated with induction chemotherapy with MMC-containing regimens.
In the entire population group, NTCP values estimated from the Lyman model with any of the published sets of parameters were not significantly correlated with the incidence of RP.
In the subgroup of 55 PTs without COPD, mean lung dose was a nearly significant
References (38)
- et al.
Strategy for dose escalation using 3-dimansional conformal radiation therapy for lung cancer
Ann Oncol
(1995) - et al.
Tolerance of normal tissue to therapeutic irradiation
Int J Radiat Oncol Biol Phys
(1991) - et al.
Radiation pneumonitis after breast cancer irradiation: analysis of the complication probability using the relative seriality model
Int J Radiat Oncol Biol Phys
(2000) Personal thoughts on normal tissue tolerance, or, what the textbooks don't tell you
Int J Radiat Oncol Biol Phys
(2001)- et al.
Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
Int J Radiat Oncol Biol Phys
(1999) - et al.
Radiation-induced pulmonary toxicity: a dose-volume histograms analysis in 201 patients with lung cancer
Int J Radiat Oncol Biol Phys
(2001) - et al.
Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis
Int J Radiat Oncol Biol Phys
(2001) - et al.
Dose-volume histogram and 3-D treatment planning evaluation of PTs with pneumonitis
Int J Radiat Oncol Biol Phys
(1994) - et al.
Physical and biological predictors of changes in whole-lung function following thoracic irradiation
Int J Radiat Oncol Biol Phys
(1997) - et al.
Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems
Int J Radiat Oncol Biol Phys
(1995)
Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis
Int J Radiat Oncol Biol Phys
The influence of age on the delivery, tolerance, an efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer
Int J Radiat Oncol Biol Phys
Factor predicting severe radiation pneumonitis in PTs receiving definitive chemoradiation for lung cancer
Int J Radiat Oncol Biol Phys
Risk factors of pneumonitis following chemoradiotherapy for lung cancer
Eur J Cancer
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials
Br Med J
Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials
Lancet
Lung toxicity following chest irradiation in patients with lung cancer
Lung Cancer
Quantitative clinical radiobiology of early and late lung reactions
Int J Radiat Biol
Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer
J Clin Oncol
Cited by (255)
Chest and thorax: Symptoms and toxicities
2023, Palliative Radiation OncologyRadiotherapy for primary lung cancer
2022, Cancer/RadiotherapiePhysics of Particle Beam and Hypofractionated Beam Delivery in NSCLC
2021, Seminars in Radiation OncologyA dynamic nomogram predicting symptomatic pneumonia in patients with lung cancer receiving thoracic radiation
2024, BMC Pulmonary MedicinePulmonary function and toxicities of proton versus photon for limited-stage small cell lung cancer
2023, Radiation Oncology Journal